Department of Parasitology-Mycology, National Reference Centre for Echinococcoses, University Hospital of Besançon, 25030 Besançon, France - UMR CNRS 6249 Laboratoire Chrono-environnement, Université Bourgogne-Franche-Comté, 16 Route de Gray, 25030 Besançon, France.
Department of Parasitology-Mycology, National Reference Centre for Echinococcoses, University Hospital of Besançon, 25030 Besançon, France.
Parasite. 2022;29:4. doi: 10.1051/parasite/2022004. Epub 2022 Feb 2.
Confirmed diagnosis of alveolar echinococcosis (AE) is based on pathological criteria and molecular evidence. This parasite-borne disease, caused by the cestode Echinococcus multilocularis, sparingly involves humans as a dead-end host. In humans, the parasite mainly colonizes the liver but can colonize any organ and cause atypical forms, often difficult to characterize clinically. Moreover, molecular methods may be suitable to make the diagnosis of AE in cases of atypical forms, extra-hepatic localizations, or immunosuppressed patients. The aim of this study was to determine the most relevant published PCR techniques, for diagnosis of AE in patients and adopt the best strategy for molecular diagnosis depending on the nature of the tested sample. In this study, we evaluated nine end-point PCR assays and one real-time PCR assay (qPCR), targeting mitochondrial genes, using a total of 89 frozen or formalin-fixed paraffin-embedded (FFPE) samples from either 48 AE or 9 cystic echinococcosis patients. Targeted fragment-genes ranged from 84 to 529 bp. Six PCR assays were able to amplify the DNA of 100% of the frozen AE-samples and for one PCR, 69.8% of the FFPE AE-samples. The 16S rrnL PCR (84 bp) was positive in PCR for 77% of the AE samples and in qPCR for 86.5%. The sensitivity of the PCR assays was higher for fresh samples and FFPE samples stored for less than 5 years. The qPCR assay further increased sensitivity for the tested samples, confirming the need for the development of an Echinococcus spp. qPCR to improve the molecular diagnosis of echinococcoses.
泡型包虫病(AE)的确诊基于病理标准和分子证据。这种寄生虫病由带绦虫多房棘球绦虫引起,人类作为终末宿主很少受到感染。在人类中,寄生虫主要定植于肝脏,但也可以定植于任何器官并引起非典型形式,这些形式在临床上往往难以确定。此外,分子方法可能适用于在非典型形式、肝外定位或免疫抑制患者中诊断 AE。本研究旨在确定最相关的已发表 PCR 技术,用于诊断患者中的 AE,并根据测试样本的性质采用最佳的分子诊断策略。在这项研究中,我们评估了九种终点 PCR 检测和一种实时 PCR 检测(qPCR),针对线粒体基因,使用总共 89 个来自 48 个 AE 或 9 个囊型包虫病患者的冷冻或福尔马林固定石蜡包埋(FFPE)样本。靶向片段基因范围从 84 到 529bp。六种 PCR 检测能够扩增 100%冷冻 AE 样本的 DNA,对于一种 PCR,69.8%的 FFPE AE 样本的 DNA 可以被扩增。16S rrnL PCR(84bp)在 77%的 AE 样本中为 PCR 阳性,在 86.5%的 qPCR 中为阳性。对于新鲜样本和储存时间少于 5 年的 FFPE 样本,PCR 检测的灵敏度更高。qPCR 检测进一步提高了测试样本的灵敏度,证实需要开发一种棘球绦虫属 qPCR,以提高包虫病的分子诊断。